Skip to main content

The Jackson Laboratory

  • Home
    • Autoimmune/Inflammation
    • Essentials
    • Immunology
    • Immuno-oncology/Oncology
    • Infectious Disease
    • Metabolic
    • Neurobiology
    • Rare Disease
    • Blog
    • Case Studies
    • Clinical Education Online Courses
    • eBooks
    • Fact Sheets
    • Guides
    • Livestream Videos
    • JAX Tech Talks
    • On-Demand Videos
    • Online MiniCourses
    • Portfolios
    • White Papers

Recent Searches

    Share this Post

    • Share on facebook
    • Share on twitter
    • Share on linkedin
    • Share on email

    AACR Annual Meeting 2023

    1. Home
    2. The Jackson Laboratory at AACR 2023
    3. Hereditary cancer syndromes: Are your patients at risk? (CME/CNE)

    Hereditary cancer syndromes: Are your patients at risk? (CME/CNE)

    Self-paced • 2.0 credits

    About this course

    This program was developed to help oncology providers identify, evaluate, and manage patients at increased risk of hereditary cancer syndromes. The program was developed by the Michigan State Department of Health and Human Services and The Jackson Laboratory Clinical and Continuing Education Program with funding from the Centers for Disease Control and Prevention.

    Genetic testing is becoming increasingly accessible for patients as the list of clinical indications and number of genes are growing, and the cost of testing is decreasing. Identifying a patient with an underlying genetic variant associated with cancer can impact his or her treatment options, long-term management approach, and risks for other cancer. In addition, there are implications for close family members. While genetic testing can provide important clinical information for decision-making, there are benefits, limitations, and risks. This program focuses on developing skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan.

     

    ACCESS CME   ACCESS CNE

     

    Learning Objectives

    Upon completion of this educational activity, the learner will be able to:

    • Determine if a patient is a candidate for cancer genetic testing
    • Deliver pre-testing counseling appropriate to the patient
    • Select the best genetic test for the patient
    • Interpret genetic testing results
    • Identify patient management based on genetic testing results

     

    Target Audience

    This activity is designed to meet the educational needs of practicing clinicians who work with cancer patients.

     

    Disclaimer

    All information in Hereditary Cancer Syndromes: Are Your Patients at Risk? is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Hereditary Cancer Syndromes: Are Your Patients at Risk?. Reliance on any information in this program is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Hereditary Cancer Syndromes: Are Your Patients at Risk?

     

    Sign up for this course today!

    ACCESS CME   ACCESS CNE
     
    • Previous Article

      Choosing the Best Genomic Tumor Test (CME/CNE)

      Choosing the Best Genomic Tumor Test (CME/CNE)

      Learn about the benefits and limitations of different genomic tumor test options for patients with cancer and how to determine the best test for each patient.

    • Next Article

      The Promise of Cancer Genomics

      The Promise of Cancer Genomics

      Learn about the advantages of using genomic-based strategies in the fight against cancer

    Other content in this Stream

    • 2023 AACR The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics
      6 months ago

      2023 AACR The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics

      Read Flipbook

    • 2023 AACR Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized m
      6 months ago

      2023 AACR Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized m

      Read Flipbook

    • 2023 AACR A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodi
      6 months ago

      2023 AACR A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodi

      Read Flipbook

    • 2023 AACR Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoi
      6 months ago

      2023 AACR Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoi

      Read Flipbook

    • 2023 AACR Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunother
      6 months ago

      2023 AACR Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunother

      Read Flipbook

    • 2023 AACR Mouse models of cancer available from The Jackson Laboratory
      6 months ago

      2023 AACR Mouse models of cancer available from The Jackson Laboratory

      Read Flipbook

    • Oncology - Preclinical Models and Services
      over 3 years ago

      Oncology - Preclinical Models and Services

      Read Flipbook

    • FcRn model platform 1:50
      6 months ago

      FcRn model platform

      The FcRn platform from The Jackson Laboratory mimics specific aspects of the human IgG physiology providing the ideal model platform to assess the pharmacokinetics (PK) of therapeutic antibody candida

      Watch Video

    • Onco-Hu Studies
      6 months ago

      Onco-Hu Studies

      Read Flipbook

    • In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety
      6 months ago

      In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

      Read Flipbook

    • PDX Models & Services
      6 months ago

      PDX Models & Services

      Read Flipbook

    • Syngeneic Tumor Studies
      over 3 years ago

      Syngeneic Tumor Studies

      Read Flipbook

    • Model Generation Services
      12 months ago

      Model Generation Services

      Our team of subject matter experts will design your new mouse model based on your research goals.

      Read Flipbook

    • AACR 2022 Poster: Age-related Immunosenescence and Cancer Drug Toxicity and Efficacy in C57BL/6J Syngeneic Model
      over 1 year ago

      AACR 2022 Poster: Age-related Immunosenescence and Cancer Drug Toxicity and Efficacy in C57BL/6J Syngeneic Model

      Read Flipbook

    • A MHC Class I & II Deficient Platform Humanized with PBMCs
      14 days ago

      A MHC Class I & II Deficient Platform Humanized with PBMCs

      JAX NSG-MHC I/II KO mice readily engraft tumors and human PBMCs, have delayed GvHD, and deliver translationally-relevant results for various research applications.

      Read Flipbook

    • Humanized NSG and NSG-SGM3 Mouse Models
      over 3 years ago

      Humanized NSG and NSG-SGM3 Mouse Models

      Humanized NSG and NSG-SGM3 mice are powerful preclinical models for studying the actions of immuno-modulators, either alone or in combination with other treatments.

      Read Flipbook

    • JAX Consulting and Advisory Services
      11 months ago

      JAX Consulting and Advisory Services

      Read Flipbook

    • Achieving Relevant Preclinical Characterization of CAR T Cell Therapies
      over 1 year ago

      Achieving Relevant Preclinical Characterization of CAR T Cell Therapies

      This whitepaper examines the constraints and challenges inherent in each CAR T study type and how to overcome them with in vivo studies using fully humanized mouse models.

      Read Flipbook

    • A New Way to Study Cytokine Release Syndrome
      over 1 year ago

      A New Way to Study Cytokine Release Syndrome

      In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most.

      Read Flipbook

    • Targeting Natural Killer Cell Activity with Humanized NSG IL-15 Mouse Model
      over 2 years ago

      Targeting Natural Killer Cell Activity with Humanized NSG IL-15 Mouse Model

      The NEW cord blood CD34+ HSC humanized NSG-IL15 mouse enables efficacy research for compounds targeting human natural killer (NK) cell activity including antibody-dependent cellular cytotoxicity.

      Read Flipbook

    Return to Home
    © The Jackson Laboratory